Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.52 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9265046 | 1.00 | NR5A1 (0.53) | NR5A1MEN1USP2ALDH1A1LMNA | |
| SCHEMBL7276099 | 1.00 | NR5A1 (0.53) | NR5A1MEN1USP2ALDH1A1LMNA | |
| SCHEMBL11319340 | 1.00 | NR5A1 (0.53) | NR5A1MEN1USP2ALDH1A1LMNA | |
| SCHEMBL11307472 | 1.00 | NR5A1 (0.53) | NR5A1MEN1USP2ALDH1A1LMNA | |
| SCHEMBL8815462 | 1.00 | NR5A1 (0.53) | NR5A1MEN1USP2ALDH1A1LMNA | |
| SCHEMBL11315075 | 0.98 | ALDH1A1 (0.50) | NR5A1MEN1USP2ALDH1A1LMNA | |
| SCHEMBL5492651 | 0.95 | RARB (0.55) | NR5A1MEN1USP2ALDH1A1LMNA | |
| SCHEMBL3188400 | 0.95 | LMNA (0.51) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL1669767 | 0.92 | MEN1 (0.55) | NR5A1MEN1USP2ALDH1A1LMNA | |
| SCHEMBL1667016 | 0.91 | MEN1 (0.57) | NR5A1MEN1USP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4297277-A | FUNGICIDES ANTISEPTICS | ELI LILLY AND COMPANY (US) | 1981-10-27 | — | — | US | claimed |
| US-4293486-A | ANTIFUNGAL PEPTIDES | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | claimed |
| US-4293484-A | ANTIFUNGAL PEPTIDES | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | claimed |
| US-4293489-A | ANTIFUNGAL PEPTIDES | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | claimed |
| US-4289692-A | CYCLIC PEPTIDE ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | claimed |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2019-08-06 | — | — | US | disclosed |
| EP-3431084-A1 | ANTIINFLAMMATORY 2-OXOTHIAZOLES | Avexxin AS (NO) | 2019-01-23 | — | — | EP | disclosed |
| US-20170166539-A1 | COMPOUND | AVEXXIN AS (NO) | 2017-06-15 | — | — | US | disclosed |
| US-9597318-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2017-03-21 | — | — | US | disclosed |
| EP-2482815-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | Avexxin AS (NO) | 2012-08-08 | — | — | EP | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| WO-2011039365-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS (NO) | 2011-04-07 | — | — | WO | disclosed |
| US-4297277-A | FUNGICIDES ANTISEPTICS | ELI LILLY AND COMPANY (US) | 1981-10-27 | — | — | US | disclosed |
| US-4293486-A | ANTIFUNGAL PEPTIDES | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-4293484-A | ANTIFUNGAL PEPTIDES | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-4289692-A | CYCLIC PEPTIDE ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| EP-0031220-A1 | Derivatives of cyclic peptide nuclei | ELI LILLY AND COMPANY (US) | 1981-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136879-A1 | COMPOUND | CBR1, CBR3, CCR1 | NR5A1 123/4885MEN1 2321/4885USP2 4093/4885 |
| US-20170166539-A1 | COMPOUND | CBR1, CBR3, CCR1 | NR5A1 124/4885MEN1 2314/4885USP2 4090/4885 |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | CX3CR1, LTC4S, CBR1 | NR5A1 199/4885MEN1 3221/4885USP2 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.